Life Sciences And Taxes

Posted: 09/29/14

Barbara Ryan is a Managing Director in healthcare capital markets and strategic communications at FTI Consulting. Last year, the global life sciences market had more M&As than ever before. Much of this action was driven by a desire to expand into new markets, and a lot was about decreasing tax liabilities through the now-infamous tactic of corporate inversion. In May, Ryan led a panel in a discussion of the life science boom, published in FTI Journal, here, and in September the Bloom Group helped her publish an article in Life Science Leader, here, about “the elephant” in the life science room.